

Michel Haig Maillard - Curriculum Vitae

1. General information

Citizenship Swiss, Romanel-sur-Morges (VD)
Date of Birth October 21st 1974
Marital Status Married, 2 children

Professional addresses

1) Gastroentérologie Beaulieu SA
Crohn and Colitis Center
Avenue Jomini 8
1004 Lausanne
+4121-6413050
mmaillard@gesb.ch

2) Department of Medicine-CHUV
Rue du Bugnon 46
1011 Lausanne, VD
Switzerland
+4121-3144714
+4179-5562193
michel.maillard@chuv.ch

Private address Avenue de Belmont 11
1009 Pully VD
Switzerland
+4121-3112823

2. Current institutional and academic qualification and function

a. Institutional

Clinical Gastroenterologist (80%) at the Crohn's and Colitis Center, Gastroentérologie Beaulieu SA, Av. Jomini 8, 1004 Lausanne.

Attending physician (médecin agréé 10%). June 2018-current. Service of immunology and allergology, Department of medicine, CHUV, Lausanne.

Attending physician (médecin agréé 10%). June 2018-current. Service of gastroenterology and hepatology, Department of medicine, CHUV, Lausanne.

Attending physician (médecin adjoint). April 2016- June 2018. Service of gastroenterology and hepatology, Department of medicine, CHUV, Lausanne.

Attending physician (médecin associé). April 2015- April 2016. Service of gastroenterology and hepatology, Department of medicine, CHUV, Lausanne.

FMH specialist in Gastroenterology and Hepatology, 2011

b. Academic

MER Clin. February 2015, UNIL-CHUV, Lausanne

Privat Docent (PD). February 2015, UNIL-CHUV, Lausanne.

Doctor in Medicine and Life Sciences (M.D.-Ph.D.): Regulatory T cell defects are associated with autoimmunity in Wiskott-Aldrich syndrome protein deficient mice, 2008, UNIL-FBM, Lausanne.

Doctor in Medicine (M.D.): Chimeric anti-TNF α antibody (infliximab) administration as a treatment of fistulizing and active Crohn's disease, 2002, UNIL-FBM, Lausanne.

3. Undergraduate education

2003-2008: M.D.-Ph.D. graduate student. UNIL-FBM, Lausanne. Thesis project conducted at Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

1993-1999: Medical School. UNIL-FBM, Lausanne, Switzerland

4. Post-graduate education

a. Main courses/employment before obtaining doctorate and/or specialist qualification

Staff physician (Chef de clinique). 2012- 2015. Service de gastroentérologie et d'hépatologie, Département de médecine, CHUV, Lausanne.

Staff physician (Chef de clinique adjoint), April 2011 to March 2012. Service de gastroentérologie et d'hépatologie, Département de médecine, CHUV, Lausanne. Prof. D. Moradpour.

Clinical Fellow, Oct 2007 to April 2008 and April 2009 to April 2011. Service de gastroentérologie et d'hépatologie, Département de médecine, CHUV, Lausanne. Profs. P. Michetti and D. Moradpour.

Research Fellow, 2004-2007, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Bachelor in Biology, 2004, UNIL-FBM, Lausanne. The role of the peroxisome-proliferator-activated receptor β in fat metabolism and leptin expression. Centre intégratif de génomique (CIG). Prof. B. Desvergnès.

Resident, Oct 2002 to Dec 2003 and April 2008 to April 2009. Department of Internal Medicine, CHUV, Lausanne. Prof. P. Nicod.

Resident, Oct 2001 to Sept 2002. Internal Medicine and Intensive Care Unit, St-Loup Hospital, Pompaples, Switzerland. Dr. A. Zwahlen.

Intern, Oct 2000 to Sept 2001. Surgery and Orthopedics, St-Loup Hospital, Pompaples, Switzerland. Dr. P. Saillen.

b. Post-doctorate and/or post-speciality courses/employment

Sept 5-7 2016, Principal investigator and promotor clinical research course. CHUV, Lausanne

2014, Co-investigator clinical research course. CHUV, Lausanne.

2009, Advanced IBD Postgraduate Course. European Crohn's and Colitis Organisation, Hamburg, Germany.

2008-2009, Postdoctoral fellowship. service of gastroenterology and hepatology, Departement of medicine. CHUV, Lausanne. D. Velin, MER1 and Prof. P. Michetti.

5. Awards

2014, IBD award of the Swiss Gastroenterology Association (SGG-SSG), Switzerland

2011, Abbott IBD Award, Switzerland

2010, Travel award. United European Gastroenterology Federation Teaching Activity on Basic Science. Cambridge, UK

2010, Best abstract. Fifth Congress of the European Crohn's and Colitis Organisation, Prague, Czech Republic

2009, SwissIBD Days Research Award, Switzerland

2005, Imedex Travel Award, 4th Annual Advances in Inflammatory Bowel Diseases, Miami, FL, USA

6. Scientific or technical functions

2019-current: European Crohn and Colitis Organisation (ECCO) National Representative

Co-President of the Scientific committee and collaborator of the Swiss IBD Cohort Study

Steering committee member, IBDnet, Switzerland

2018: Scientific committee member, Swiss Gastroenterology Group (SGG-SSG) Congress

2011-2017: Steering committee member, Swiss Study Group for Coloproctology

2013-2015: Local investigator, Influence of immunosuppressive treatment on immunological response to pneumococcal conjugated vaccine (PCV13) in patients with inflammatory bowel disease. PI: Dr Klara Posfay-Barbe, HCUGE.

Grant and abstract reviewer for the European Crohn's and Colitis Organisation, the UEG foundation

Reviewer (*journals with editorial policy*): Mucosal Immunology, Inflammatory Bowel Diseases, Clinical Immunology, PlosOne, Expert review of Gastroenterology & Hepatology, World J Gastroenterology, World J Surgery, J Crohn and Colitis, UEG journal

7. Scientific societies Membership

2014 to date. Swiss Gastroenterology Society (SGG-SSG)

2013 to date. IBDnet, Switzerland

2008 to date. European Crohn's and Colitis Organisation (ECCO)

2006-2010. American Gastroenterology Association (AGA)

2006-2009. Crohn's and Colitis Foundation of America

8. Lecture invitations (past 3 years)

1. Sept 12-13, 2019. Speaker. Swiss Society of Gastroenterology (SSG) and ASPE-SVPE Congress. Interlaken
2. Nov 11, 2018. Iron deficiency anemia. Internal Medicine update Refresher. Palais de Beaulieu, Lausanne
3. Sept 22-23, 2018. Speaker and Chair. Swiss Society of Gastroenterology (SSG) and ASPE-SVPE Congress. Interlaken
4. June 3, 2018. Role of the gut microbiota on autistic spectrum disorders. Centre cantonal autisme, CHUV, Lausanne
5. June 2, 2018. Abdominal pain. Swiss Medical Forum, Palais de Beaulieu.
6. May 29, 2018. Irritable bowel syndrome. Post-graduate education. Groupe vaudois d'allergo-immunologie.
7. March 15, 2018. The year in obesity : The gastroenterologist point-of-view. CHUV
8. March 8, 2018. Endoscopic screening of colitis-associated cancer. Gastroenterology Symposium, CHUV.
9. March 1, 2018. Fecal transplantation : past, present and future. Department of internal Medicine, CHUV.
10. February 16, 2018. Swiss IBD brunch : ECCO highlights, Vienna.
11. October 26, 2017. Role of IL-17 in inflammatory bowel diseases. Psoriasis day, CHUV
12. October 18, 2017. Current treatment of IBD. CHUV, Lausanne
13. September 26, 2017. Management of diarrhea and constipation. Swiss Medical Forum, Lausanne.
14. March 18, 2017. Gluten, lactose and fructose intolerance. Public conference, food allergy conference, Bulle
15. March 3, 2017. CMV colitis : Myth or reality ? Gastroenterology symposium, CHUV.
16. January 19, 2017. Gluten-related disorders. CHUV, Lausanne.
17. November 2, 2016. Cyclosporine in IBD. Wolfsberg postgraduate course.
18. October 6, 2016. The microbiota and traveler's diarrhea. CHUV, Lausanne.
19. Sept 22-23, 2016. Speaker and Chair. Swiss Society of Gastroenterology (SSG) and ASPE-SVPE Congress. Interlaken
20. Sept 14, 2016. Speaker. SMCCV congress. Lausanne
21. August 15, 2016. Postgraduate course on acute pancreatitis. Internal Medicine, CHUV, Lausanne.
22. June 14, 2016. Gastrointestinal side effects of immunotherapies. Interdisciplinary symposium. CHUV, Lausanne
23. May 20, 2016. Reciprocal role of Tollip in colitis and colorectal cancer development. Resal training on animal experimentation, CHUV, Lausanne
24. March 9, 2016. Non-dietary approaches to celiac disease. CHUV, Lausanne
25. February 4, 2016. Non-celiac gluten sensitivity : A Myth ! IBD Symposium CHUV, Lausanne

9. Conference papers (last 5 years)

1. Valerie Pittet, **Michel H Maillard**, Pierre Michetti. Systematic assessment of patient self-reported signs, symptoms, and nutrition behavior. [poster presentation]. 15th Congress of ECCO, March 6-9 2019, Copenhagen. Abstract published in Journal of Crohn s and Colitis 13(Supplement_1):S226-S227
2. Daniele Jelk, Matthieu Perreau, Pierre Michetti, **Michel H Maillard**. Clinical utility of vedolizumab trough levels and anti-drug antibodies in the management of IBD. [poster presentation]. 14th Congress of ECCO, february 14-17 2018, Vienna. Abstract published in Journal of Crohn s and Colitis

3. Christina Begka, Simone Ragusa, Yan Pu, Tatiana Petrova, Stéphane Nancey, Dominique Velin, **Michel H Maillard**. Toll-interacting protein promotes colitis-associated cancer by regulating immune cell infiltration. [Oral presentation]. 14th Congress of ECCO, february 14-17 2018, Vienna. Abstract published in Journal of Crohn s and Colitis 12(supplement_1):S086-S087
4. Danièle Jelk, Matthieu Perreau, Pierre Michetti & **Michel H. Maillard**. Clinical utility of vedolizumab trough levels and anti-drug antibodies in the management of IBD. 13th Congress of ECCO, Vienna, February 14-17 2017 (Abstract published in J Crohn's and Colitis)
5. C. Begka, Y. Pu, S. Ragusa, T. Petrova, D.Velin and **M.H. Maillard** . Toll-interacting protein promotes colitis-associated cancer by regulating immune cell infiltration [oral presentation]. 13th Congress of ECCO, Vienna, February 14-17 2017 (Abstract published in Journal of Crohn s and Colitis 12(supplement_1):S086-S087)
6. C. Begka*, Y. Pu, S. Ragusa, T. Petrova, D.Velin and **M.H. Maillard**. Toll-interacting protein Deficiency Protects Mice from Colitis-associated Cancer by Modulating anti-tumoral Immune Regulation [oral presentation]. UEGW, October 17-19, 2016 (Abstract published in UEG journal) * Travel Grant of €1000
7. G. Santi, P. Michetti, F. Froehlich, G. Dorta, V. Pittet and **M. H. Maillard**. Adherence to Recommendations and Quality of Endoscopic Colorectal Cancer Surveillance in Long-standing Ulcerative Colitis [poster presentation]. UEGW, October 17-19, 2016 (Abstract published in UEG journal)
8. G. Santi, P. Michetti, F. Froehlich, G. Dorta, V. Pittet and **M. H. Maillard**. Adherence to Recommendations and Quality of Endoscopic Colorectal Cancer Surveillance in Long-standing Ulcerative Colitis [Oral presentation]. Annual SGG/SSG Congress 2016. Interlaken, September 22-23, 2016
9. V. Pittet, C. Vaucher, F. Froehlich, B. Burnand, P. Michetti, **M. H. Maillard**. Worries of patients with inflammatory bowel disease: an indicator of well-being? Results of survey amongst 1 096 participants in a European bilingual clinical cohort. 11th Congress of ECCO, Amsterdam, March 16-19 2016 (Abstract published in J Crohn's and Colitis)
10. V. Pittet, C. Vaucher, **M. H. Maillard**, F. Froehlich, B. Burnand, P. Michetti. Healthcare expectations of patients with inflammatory bowel disease: a survey amongst 1089 participants in a European bilingual clinical cohort. 11th Congress of ECCO, Amsterdam, March 16-19 2016 (Abstract published in J Crohn's and Colitis)
11. M. Timmer, F. Froehlich, P. Michetti, **M. H. Maillard**, A. Schoepfer, C. Mottet, B. Burnand, V. Pittet. Routine assessment of inflammatory boweldiseases clinical presentations: a prerequisite to check for treatment recommendations. 11th Congress of ECCO, Amsterdam, March 16-19 2016 (Abstract published in J Crohn's and Colitis)
12. Vaucher C, **Maillard MH**, Timmer M, Froehlich F, Burnand B, Michetti P, Pittet V. Patients and gastroenterologists' perception of treatments in inflammatory bowel disease: Do doctors and patients speak the same language? Digestive Disease Week, USA. 2015 (Abstract published in Gastroenterology 2015; 148: S208)
13. Guirgis M, Bianchetti D, Dorta G, Michetti P, **Maillard MH**. Clinical impact of routine anti-TNF therapeutid drug monitoring in management of IBD patients. Digestive Disease Week, USA. 2015 (Abstract published in Gastroenterology 2015; 148: S857-S858)
14. **Maillard MH**, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B, Froehlich F, Michetti P, Pittet V. Appropriateness and Long-term Discontinuation Rate of Biological Therapies in Ulcerative Colitis. 9th Congress of ECCO. Copenhagen, February 20-22, 2014. (Abstract published in Journal of Crohn's and Colitis 2014; 8: S299-S300)

10. Teaching activities

b1) pre-graduate

2017- Supervisor and tutor of a Medical master's student (Killian Heimgartner)

2016-2018. Supervisor and tutor of a Medical master's student (Danièle Jelk)

2015. Supervisor and tutor of a biology pre-master's student (Annick Canapini)

2013-2015. Supervisor and co-tutor of a Medical master's student (Davide Bianchetti)

Teaching :

Bachelor of biology. Bsc3, M4. Troubles digestifs. 4h.

B3.2. Hémorragie digestive. 1h

B3.2. Syndrome de l'intestin irritable. 1h

B3.9. Maldigestion/malabsorption. 2h

M2.6. Cours coordonné sur les pathologies oncologiques M2.6: le cancer gastrique. 1h

CAS in endoscopy (nurses): The colon.

b2) post-graduate

2018-current. MD Thesis director. Mrs Emilie Caloz

2013-2018 PhD Thesis director. Mrs Hristina Bega

2015-2019 MD Thesis director. Mrs Giulia Santi

2019-current Organiser of IBD round tables in Romandie (Rencontres MICI romandes)

2019-current Organiser of IBDnet Talks, a Swiss-wide IBDnet-endorsed visioconference teaching

August 17, 2015 Post-graduate course for internal medicine residents. Chronic Diarrhea, 1h.

2013 to date Coordinator of the guidelines and standard operating procedures (cahiers des charges) of the Service de gastroentérologie et d'hépatologie, CHUV (www.gastro-hepato.ch)

Dec 2009 External expert in the jury of HDR (habilité à diriger des recherches) of Stéphane Nancey, MD-PhD entitled: "Mechanisms of intestinal inflammation onset and regulation in the course of inflammatory bowel diseases". University of Lyon, France

11. Publications

Original articles

1. Pillai N, Lupatsch JE, Dusheiko M, Schwenkglenks M, **Maillard M**, Sutherland CS, Pittet VEH; Swiss IBD Cohort study group. Evaluating the cost-effectiveness of early compared to late or no biologic treatment to manage Crohn's disease using real world data. *J Crohns Colitis*. 2019 [Epub ahead of print]
2. Greuter T, **Maillard MH**, Juillerat P, Michetti P, Seibold F, Mottet C, Zahnd N, Sauter B, Schoepfer AM, Rogler G, Vavricka SR. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus. *Digestion*. 2019 ; 28:1-9.
3. Pittet LF, Verolet CM, Michetti P, Girardin M, Juillerat P, Mottet C, **Maillard MH**, Siegrist CA, Posfay-Barbe KM. High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease. *Am J Gastroenterol*. 2019; 114(7):1130-1141.
4. Pillai N, Dusheiko M, **Maillard MH**, Rogler G, Brüngger B, Bähler C, Pittet VEH. The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years. *J Crohn and Colitis* 2019;13(6):744-754
5. Martins F, Sofiya L, Sykiotis GP, Lamine F, **Maillard M**, Fraga M, Shabafrouz K, Ribi C, Cairolì A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. *Nat Rev Clin Oncol*. 2019 Sep;16(9):563-580.
6. Yilmaz B, Juillerat P, Øyås O, Ramon C, Bravo FD, Franc Y, Fournier N, Michetti P, Mueller C, Geuking M, Pittet VEH, **Maillard MH**, Rogler G; Swiss IBD Cohort Investigators, Wiest R, Stelling J, Macpherson AJ. **Microbial network disturbances in relapsing refractory Crohn's disease**. *Nat Med*. 2019 Jan 21. (Epub ahead of print)
7. Martins F, Sykiotis GP, **Maillard M**, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. **New therapeutic perspectives to manage refractory immune checkpoint-related toxicities**. *Lancet Oncol*. 2019;20(1):e54-e64.
8. Pittet V, **Maillard MH**, Simonson T, Fournier N, Rogler G, Michetti P. Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals. *Clin Gastroenterol Hepatol*. 2018 Nov 21. (Epub ahead of print)

9. Pittet V, Vaucher C, Froehlich F, **Maillard MH**, Michetti P. Patient-reported healthcare expectations in inflammatory bowel diseases. *PLoS One*. 2018 May 17;13(5):e0197351
10. Pittet V, Vaucher C, Froehlich F, Burnand B, Michetti P and **Maillard MH**. Patient self-reported concerns in inflammatory bowel diseases: a gender-specific subjective quality-of-life indicator. *Plos ONE*, 2017 10;12(2):e0171864.
11. Humbert-Claude M, Duc D, Dwir D, Thieren L, Sandström von Tobel J, Begka C, Legueux F, Velin D, **Maillard MH**, Do KQ, Monnet-Tschudi F, Tenenbaum L. Tollip, an early regulator of the acute inflammatory response in the substantia nigra. *J Neuroinflammation*. 2016 ; 13(1):303.
12. Vaucher C, **Maillard MH**, Froehlich F, Burnand B, Michetti P, Pittet V. Patients and gastroenterologists' perceptions of treatments for inflammatory bowel diseases: do their perspectives match? *Scand J Gastroenterol*. 2016 ; 19:1-6.
13. Pittet V, Vaucher C, **Maillard MH**, Girardin M, de Saussure P, Burnand B, Rogler G, Michetti P. Information Needs and Concerns of Patients with Inflammatory Bowel Disease: What Can We Learn from Participants in a Bilingual Clinical Cohort? *PLoS ONE*. 2016 Mar 3;11(3):e0150620.
14. Allam R, **Maillard MH**, Tardivel A, Wang Yu C, Schneider P, Velin D and Maslowski KD. Epithelial Naips protect against colonic tumorigenesis. *J Exp Med*. 2015;212:369-83.
15. Pittet V, **Maillard MH**, Burnand B, Michetti P, Froehlich F, Mottet C. Acceptance of inflammatory bowel disease treatment recommendations based on appropriateness ratings: Do practicing gastroenterologists agree with experts? *J Crohn's & Colitis*, 2015; 9(2):132-9.
16. **Maillard MH**, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B, Froehlich F, Michetti P, Pittet V. Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis. *J Crohns Colitis* 2014, 8:825-34.
17. **Maillard MH***, Bega H, Uhlig H, Barnich N, Grandjean T, Chamailard M, Michetti P and Velin D*. Toll-interacting protein modulates colitis susceptibility in mice. *Inflamm Bowel Dis* 2014;20:660-70. * corresponding authors
18. Pittet V, Froehlich F, **Maillard MH**, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B, Michetti P, Schoepfer A. When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel. *J Crohns Colitis* 2013;7:820-6.
19. D'Angelo F, Bernasconi E, Schäfer M, Moyat M, Michetti P, **Maillard MH**, Velin D. Macrophages promote epithelial repair through hepatocyte growth factor secretion. *Clin Exp Immunol* 2013;174:60-72
20. Perreau M, Rozot V, Welles HC, Belluti-Enders F, Vigano S, **Maillard M**, Dorta G, Mazza-Stalder J, Bart PA, Roger T, Calandra T, Nicod L, Harari A. Lack of Mycobacterium tuberculosis-specific interleukin-17A-producing CD4+ T cells in active disease. *Eur J Immunol* 2013;43:939-48
21. Perreau M, Welles HC, Harari A, Hall O, Martin R, **Maillard M**, Dorta G, Bart PA, Kremer EJ, Tartaglia J, Wagner R, Esteban M, Levy Y, Pantaleo G. DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell responses in Intestinal Mucosa. *J Virol* 2011;85:9854-62
22. Velin D, Narayan S, Bernasconi E, Busso N, Ramelli G, **Maillard MH**, Bachmann D, Pythoud C, Bouzourene H, Michetti P, So A. PAR2 Promotes vaccine-induced protection against Helicobacter infection in mice. *Gastroenterology* 2011;141:1273-82
23. Bernasconi E, Favre L, **Maillard MH**, Bachmann D, Pythoud C, Bouzourene H, Croze E, Velichko S, Parkinson J, Michetti P, Velin D. Granulocyte-macrophage colony stimulating factor elicits bone-marrow derived cells that promote efficient colonic mucosal healing. *Inflamm Bowel Dis* 2010;16:428-4
24. Nguyen DD, **Maillard MH**, Cotta-de-Almeida V, Mizoguchi E, Klein C, Mizoguchi A, Bhan AK and Snapper SB. Lymphocyte-Dependent and Th2 Cytokine-Associated Colitis in Mice Deficient in Wiskott-Aldrich Syndrome Protein. *Gastroenterology* 2007;133:1188-97.
25. Cotta-de-Almeida V, **Maillard MH***, Westerberg L*, Onaldi D, Wachtel H, Meelu P, Chung U-I, Xavier R, Alt FW and Snapper SB. WASP and N-WASP are critical for T cell development. *Proc Natl Acad Sci* 2007;104:15424-9. *equal contribution
26. **Maillard MH***, Cotta-de-Almeida V*, Takeshima F, Nguyen DD, Michetti P, Nagler C, Bhan AK and Snapper SB. The Wiskott Aldrich syndrome protein is required for the function of CD4⁺CD25⁺Foxp3⁺ regulatory T cells. *J Exp Med* 2007;204:381-91. *equal contribution
 Related research highlight: Minton K. WASP helps T_{Reg} cells sting their prey. *Nat Rev Immunol* 2007;7:253.
27. **Maillard M**, Vu F, Pascual M, Michetti P, Felley C. New onset inflammatory bowel disease post liver transplantation : Case Reports and Review of the Literature. *Gastroenterol Clin Biol* 2006;30:1096-101.

Review articles and editorials

1. Moschouri E, Hessler R, Pittet V, Velin D, Conrad C, Hahnloser D, Gié O, Michetti P, Schoepfer AM, **Maillard MH**. Management of ulcerative colitis in 2017. *Rev Med Suisse*. 2017, 13:1480-1486.
2. Parliteanu C, Gavillet M, Gié O, Bize P, **Maillard MH**. Diagnostic and treatment of mesenteric ischemia. *Rev Med Suisse*. 2016, 12:1419-1423.
3. Begka C, Velin D, **Maillard MH**. Preventing Overheating: Tight Control of Gut Innate Immunity in Health and Disease. *Inflamm Bowel Dis* 2016, 22:1723-36.
4. Cunningham S, Maulucci F, Zufferey P, Ribi C, **Maillard MH**. Whipple's disease: When to think about it. *Rev Med Suisse* 2015; 484: 1582-1587
5. Fraga M, Nydegger A, Abdelrahman K, Burgmann K, **Maillard MH**, Dorta G. Digestive foreign body management. *Rev Med Suisse* 2015; 484: 1592-95
6. Moura B, Homicsko K, Berthod G, Cerottini JP, Guggisberg D, Gaide O, **Maillard MH**, Michielin O. New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities. *Rev Med Suisse*. 2015;11: 1110-4.
7. Tissot F, **Maillard MH**. Clostridium Difficile Colitis : New treatment recommendations. *Rev Med Suisse* 2014; 10: 913-919.
8. Maitre S, Maniu CM, Buss G, **Maillard MH**, Spertini F, Ribi C. Food allergy or food intolerance ? *Rev Med Suisse* 2014; 10: 846-53
9. Godat S, Velin D, Aubert V, Nydegger A, Schoepfer AM, **Maillard MH**. An update on celiac disease. *Rev Med Suisse* 2013;9:1584-9
10. **Maillard MH**, Hiroz P, Wagner D, Prior J, Boubaker A, Pralong F, Dorta G, Nichita C. Gastrointestinal neuroendocrine tumors: pleomorphic and often ignored. *Rev Med Suisse* 2012;8:1658-63.
11. Kessler Brondolo V, **Maillard MH**, Delarive J, Mottet C, Michetti P. Inflammatory bowel disease: a "survival kit" for general practitioners. *Rev Med Suisse* 2010;6:180-2, 184-5
12. Felley C, Mottet C, Hess J, **Maillard MH**, Delarive J, Michetti P. Main therapeutic advances in IBD in 2008. *Rev Med Suisse* 2009;5:185-6, 188-90, 192-4
13. Felley C, Mottet C, **Maillard MH**, Hess J, Delarive J, Michetti P. Main therapeutic advances in IBD in 2007. *Rev Med Suisse* 2008;4:200, 202-4.
14. **Maillard MH** and Snapper SB. Teaching tolerance with a probiotic antigen delivery system. *Gastroenterology* 2007,133:706-9
15. **Maillard MH**. Les résolvines : nouveaux dérivés des acides gras polyinsaturés (oméga-3) au potentiel thérapeutique dans les maladies inflammatoires intestinales. *Rev Med Suisse* 2006;2:2634-5
16. **Maillard MH**. La pancréatite auto-immune : une nouvelle entité clinique. *Rev Med Suisse* 2006;2:1759-60

Book chapter

Maillard MH and Snapper SB. Inflammatory Bowel Disease: Translating Basic Science into Clinical Practice. Chapter 10: Cytokines and Chemokines in Mucosal Homeostasis. Wiley Blackwell Edition, April 2010